OBJECTIVES: We describe a novel microarray-based approach for the high-throughput discovery of epigenetic biomarkers for use in the noninvasive detection of fetal genetic disease. METHODS: We combined a 215 060-probe custom oligonucleotide microarray with a comprehensive library preparation method and novel statistical tools to compare DNA methylation patterns in chorionic villus samples (CVS) with gestational age-matched maternal blood cell (MBC) samples. Our custom microarray was designed to provide high-resolution coverage across human chromosomes 13, 18 and 21. RESULTS: We identified 6311 MspI/HpaII sites across all three chromosomes that displayed tissue-specific differential CpG methylation patterns. To maximize the probability of identifying biomarkers that have clinical utility we filtered our data to identify MspI/HpaII sites that are within 150 bp of a highly polymorphic single nucleotide polymorphism (SNP) so that its allelic ratio may be determined for the detection of fetal aneuploidy. Our microarray design and the computational tools used for data analysis are available for download as is the entire data set. CONCLUSIONS: This high-resolution analysis of DNA methylation patterns in the human placenta during the first trimester of pregnancy identifies numerous potential biomarkers for the diagnosis of fetal aneuploidy on chromosomes 13, 18 and 21.
OBJECTIVES: We describe a novel microarray-based approach for the high-throughput discovery of epigenetic biomarkers for use in the noninvasive detection of fetal genetic disease. METHODS: We combined a 215 060-probe custom oligonucleotide microarray with a comprehensive library preparation method and novel statistical tools to compare DNA methylation patterns in chorionic villus samples (CVS) with gestational age-matched maternal blood cell (MBC) samples. Our custom microarray was designed to provide high-resolution coverage across human chromosomes 13, 18 and 21. RESULTS: We identified 6311 MspI/HpaII sites across all three chromosomes that displayed tissue-specific differential CpG methylation patterns. To maximize the probability of identifying biomarkers that have clinical utility we filtered our data to identify MspI/HpaII sites that are within 150 bp of a highly polymorphic single nucleotide polymorphism (SNP) so that its allelic ratio may be determined for the detection of fetal aneuploidy. Our microarray design and the computational tools used for data analysis are available for download as is the entire data set. CONCLUSIONS: This high-resolution analysis of DNA methylation patterns in the human placenta during the first trimester of pregnancy identifies numerous potential biomarkers for the diagnosis of fetal aneuploidy on chromosomes 13, 18 and 21.
Authors: Ming Zhang; Tao Li; Jingyi Chen; Li Li; Chun Zhou; Yan Wang; Wenhui Liu; Yuanzhen Zhang Journal: J Huazhong Univ Sci Technolog Med Sci Date: 2011-10-25
Authors: Ji Hyae Lim; Bom Yi Lee; Jin Woo Kim; You Jung Han; Jin Hoon Chung; Min Hyoung Kim; Dong Wook Kwak; So Yeon Park; Hee Back Choi; Hyun Mee Ryu Journal: J Assist Reprod Genet Date: 2018-02-08 Impact factor: 3.412
Authors: Tianjiao Chu; Daniel Handley; Kimberly Bunce; Urvashi Surti; W Allen Hogge; David G Peters Journal: PLoS One Date: 2011-02-23 Impact factor: 3.240
Authors: Boris Novakovic; Ryan K Yuen; Lavinia Gordon; Maria S Penaherrera; Andrew Sharkey; Ashley Moffett; Jeffrey M Craig; Wendy P Robinson; Richard Saffery Journal: BMC Genomics Date: 2011-10-28 Impact factor: 3.969
Authors: Shengnan Jin; Yew Kok Lee; Yen Ching Lim; Zejun Zheng; Xueqin Michelle Lin; Desmond P Y Ng; Joanna D Holbrook; Hai Yang Law; Kenneth Y C Kwek; George S H Yeo; Chunming Ding Journal: PLoS Genet Date: 2013-06-06 Impact factor: 5.917